OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeted Protein Degradation: Clinical Advances in the Field of Oncology
Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15440-15440
Open Access | Times Cited: 15
Abdelrahman K. A. A. Salama, Marija V. Trkulja, Emilio Casanova, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15440-15440
Open Access | Times Cited: 15
Showing 15 citing articles:
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 20
Yujeong Moon, Seong Ik Jeon, Man Kyu Shim, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 411-411
Open Access | Times Cited: 20
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 15
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 15
Inhibitors to degraders: Changing paradigm in drug discovery
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 6
V. Haridas, Souvik Dutta, Akshay Munjal, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109574-109574
Open Access | Times Cited: 6
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Transcription factors in fibroblast plasticity and CAF heterogeneity
Roberta Melchionna, Paola Trono, Anna Di Carlo, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 15
Roberta Melchionna, Paola Trono, Anna Di Carlo, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 15
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Targeted Degradation of Structured RNAs via Ribonuclease-Targeting Chimeras (RiboTacs)
Salma Haj-Yahia, Arijit Nandi, Raphael I. Benhamou
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 929-942
Closed Access | Times Cited: 9
Salma Haj-Yahia, Arijit Nandi, Raphael I. Benhamou
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 929-942
Closed Access | Times Cited: 9
SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Saumya Easaw, Shawyon Ezzati, Catherine C. Coombs
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 10, pp. 697-704
Closed Access | Times Cited: 6
Saumya Easaw, Shawyon Ezzati, Catherine C. Coombs
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 10, pp. 697-704
Closed Access | Times Cited: 6
Development of natural product-based targeted protein degraders as anticancer agents
Cheng Chen, Yanyan Feng, Chen Zhou, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107772-107772
Closed Access | Times Cited: 1
Cheng Chen, Yanyan Feng, Chen Zhou, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107772-107772
Closed Access | Times Cited: 1
Genetic manipulation and targeted protein degradation in mammalian systems: practical considerations, tips and tricks for discovery research
Stefano L. Giandomenico, Erin M. Schuman
FEBS Open Bio (2023) Vol. 13, Iss. 7, pp. 1164-1176
Open Access | Times Cited: 2
Stefano L. Giandomenico, Erin M. Schuman
FEBS Open Bio (2023) Vol. 13, Iss. 7, pp. 1164-1176
Open Access | Times Cited: 2
Targeted protein degradation: current molecular targets, localization, and strategies
Dimanthi Pliatsika, Cindy Blatter, Rainer Riedl
Drug Discovery Today (2024), pp. 104178-104178
Open Access
Dimanthi Pliatsika, Cindy Blatter, Rainer Riedl
Drug Discovery Today (2024), pp. 104178-104178
Open Access
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1701-1701
Open Access
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1701-1701
Open Access
Targeted nanoliposomes of oncogenic protein degraders: Significant inhibition of tumor in lung-cancer bearing mice
Richa Vartak, Ketan Patel
Journal of Controlled Release (2024) Vol. 376, pp. 502-517
Closed Access
Richa Vartak, Ketan Patel
Journal of Controlled Release (2024) Vol. 376, pp. 502-517
Closed Access
Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics
Atharva A. Mahajan, Gauri Panzade, Tiyasa Bhuniya, et al.
Current Problems in Cancer (2024) Vol. 54, pp. 101172-101172
Closed Access
Atharva A. Mahajan, Gauri Panzade, Tiyasa Bhuniya, et al.
Current Problems in Cancer (2024) Vol. 54, pp. 101172-101172
Closed Access
Targeted Protein Degraders- The Druggability Perspective
Satinder Singh, Pratima Srivastava
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 539-554
Closed Access
Satinder Singh, Pratima Srivastava
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 539-554
Closed Access
